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Abstract
Background: The ocular presentation of Castleman’s disease (CD)-associated paraneoplastic pemphigus (PNP) has
rarely been reported. In this report, we describe a young patient with CD-associated PNP who had recurrent corneal
ulceration in addition to cicatrizing conjunctivitis.
Case presentation: We describe a case of 23-year-old male with mucocutaneous erosion and conjunctival injection
and erosion who was found to have PNP. Pelvic hyaline-vascular CD was detected and completely excised. The
mucocutaneous lesions improved postoperatively. Two years after pelvic surgery, the patient gradually developed
conjunctival symblepharon in both eyes and pterygium in the right eye. The patient then underwent a successful
exclusion of the symblepharon, an excision of the pterygium and an amniotic membrane transplantation in
the right eye. However, after 6 months, he experienced an aseptic corneal ulcer and recurrent pterygiumin
the right eye. After treatment with systemic and local immunosuppressive medications, the corneal ulcer gradually
healed and remained stable.
Conclusion: Corneal ulceration and melting, in addition to conjunctivitis, as a complication of CD-associated PNP, can
be successfully managed with systemic and local immunosuppressants.
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Background
Paraneoplastic pemphigus (PNP) is a new autoimmune
mucocutaneous blistering disease associated with
neoplasms, such as Castleman’s disease (CD) [1–3]. PNP
is characterized by distinctive clinical symptoms and
signs, such as severe and painful mucosal erosions and
polymorphous skin lesions [1, 2].
Cicatrizing conjunctivitis is the main ocular presenta-
tion of PNP [4], and only one case of bilateral corneal
melting has been reported in a patient with PNP and a
peripheral neuronal shaft tumor [5]. However, the ocular
involvement of CD-associated PNP has rarely been
reported. In this report, we describe a young patient
with CD-associated PNP who developed recurrent
corneal ulceration in addition to conjunctivitis after the
resection of the tumor.
Case presentation
In November 2011, a 23-year-old man presented with
persistent, painful oral erosions resistant to systemic
corticosteroid and antibiotic treatment. Conjunctival
congestion and erosion was also present, but there were
no other ocular abnormalities on slit-lamp and direct
fundoscopic examinations. Local antibiotic eye drops
and ointment were given. Erosion on the fingers in both
hands appeared later.
The serum markers for rheumatic diseases, cancer, HIV
and syphilis infection were negative. A histological exam-
ination of a buccal mucosal biopsy with hematoxylin-
eosin staining showed a small mucous membrane ulcer
formation, lichenoid interface infiltration and keratinocyte
necrosis (Fig. 1a). Serum antibodies against desmoglein
(Dsg)-3 were detected by ELISA, but anti-Dsg-1 anti-
bodies were not found. Indirect immunofluorescence (IIF)
demonstrated IgG autoantibodies directed toward rat
bladder transitional cell epithelium. The patient was
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diagnosed with PNP according the criteria for the diagno-
sis of PNP proposed by Camisa and Helm [6].
An MRI revealed a pelvic mass (4.9 × 3.7 × 5.1 cm) that
was located in the area of the right iliac vessels, and it
had well-defined border (Fig. 1b). The patient subse-
quently underwent a complete excision of the pelvic
mass after receiving intravenous gamma globulin (20 g
daily for 3 days). A histopathologic examination revealed
a lymph node specimen constituted by small-sized
follicles with regressed germinal centers and “onion
skin” arrangement mantle zone lymphocytes. The germi-
nal centers were almost totally replaced by endothelial
and dendritic cells. Blood vessels with hyalinized walls
also penetrated into regressed germinal centers forming
a hyaline-vascular lesion. The inter follicular stroma
abounded in numerous high endothelial venules with
sclerotic walls. No normal lymphoid tissue or lymph
node sinus was recognized circumferentially. No plasma
cell sheets were detected (Fig. 1c). Therefore, the hyaline
vascular variant of CD was diagnosed. Then, after the
conjunctival erosion was cured and the injection was
alleviated, local antibiotic treatment ceased 4 weeks
postoperatively. The patient’s mucosal and nail lesions
had gradually improved by 5 months after the surgery
(Fig. 2a, b). Postoperative management consisted of oral
prednisone (50 mg daily) and cyclosporine (150 mg
daily), which were gradually tapered. IgG antibody direct
to rat bladder transitional cell epithelium was examined
for several times, the titer decreased significantly from
1:320 before pelvic surgery to 1:80 2 years after surgery,
and varied from 1:10 to 1:80 during the following
follow-up. While anti-Dsg3 antibody was not routinely
tested since it is not critical among the antibody
spectrum of PNP.
In August 2013, 2 years after the pelvic surgery, the
patient was admitted to our hospital’s Department of
Ophthalmology with a symblepharon of the lateral
canthus in the both eyes and temporal pterygium in
the right eye (Fig. 3a). The size of the pterygium,
measured from limbus to the head of pterygium, was
4 mm at its longest diameter. Both the anterior
chamber and fundus examinations were normal.
Considering the conjunctival inflammation inactive,
the surgery, including an exclusion of the symblepharon,
an excision of the pterygium, and amniotic membrane
grafting, was successively performed in the right eye.
Tobramycin-dexamethasone eye drops (TobraDex; Alcon
Laboratories, Inc., Fort Worth, TX, USA) and nonsteroidal
anti-inflammatory eye drops (Pranoprofen eye drops;
Senju Pharmaceutical Co, Ltd, Osaka, Japan) were admin-
istered postoperatively, tapered gradually and stopped
4 weeks postoperatively.
Fig. 1 The imaging and pathological features. a Formation of small mucous membraneulcers, lichenoid interface infiltration and keratinocytenecrosis
(hematoxylin-eosin stain; original magnification × 40). b Pelvic MRI (the red arrow indicates the 4.9 × 3.7 × 5.1 cm tumor). c Histology revealed
small-sized follicles with hyalinized germinal centers and “onionskin” arrangement mantle zone lymphocytes in addition to interfollicular
hypervascularity without plasma cell sheets. (hematoxylin-eosinstain; original magnification × 100)
Fig. 2 The mucosa and skin presentation. a The oral erosion resolved, leaving an oral mucosal scar. b The nail erosions were resolved, and the
nail plates were lost bilaterally
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In February 2014, 6 months after ocular surgery, the
patient complained of pain and decreased vision in the
right eye. A slit-lamp examination revealed conjunctival
congestion, recurrent pterygium and a 2 mm-diameter
aseptic corneal ulcer in the nasal-paracentral non-
surgical area (Fig. 3b). There were no signs of ciliary
injection and no conjunctival secretions. Initially, the
administration of TobraDex eye drops every 2 h per day
for 1 week and a bandage contact lens for 3 day failed to
treat the corneal ulcer. Then, 0.1 % tacrolimus eye drops
(prepared by the hospital) were prescribed instead of
corticosteroid eye drops. The corneal ulcer gradually
healed, with the remission of eye pain and an improve-
ment in vision. However, once treatment with the tacro-
limus eye drops was discontinued, the corneal ulcer
recurred. Therefore, a topical 0.1 % tacrolimus twice per
day and a 1 % cyclosporine ointment were prescribed. The
same therapy was also applied to the left eye to treat a
minor recurrence in the left eye. To date, the corneal
melting has been stable for 6 months, with an intact epi-
thelium, local corneal thinning and temporal pterygium in
the right eye (Fig. 3c), as well as mild bilateral conjunctival
congestion and posterior capsular lens opacity. A slight
symblepharon developed in the left eye. The posterior
capsular lens opacity was thought to be due to long-term
systemic corticosteroid therapy, while the IOP in both
eyes was normal. The patient was followed closely.
Currently, he is on systemic methylprednisone 16 mg
daily, thalidomide 75 mg twice per day and methotrexate
10 mg weekly to treat oral erosions and ocular lesions. No
evidence of tumor recurrence has been found on multiple
follow-up pleural and abdominal CT and MRI scans. The
results of routine laboratory testing have been normal.
Autoantibodies against rat bladder transitional epithelium
remain positive (with a low titer of 1:10).
Discussion
Limited studies of CD-associated PNP have been
reported. In addition, the ocular presentation has not
been reported relating CD-associated PNP. Conjunctival
injections and erosions have been mentioned in some
cases of CD-associated PNP [7–9]. As far as we know,
this report is the first that examines unilateral corneal
ulceration and melting, in addition to cicatrizing
conjunctival lesions, in CD-associated PNP.
The most common causes of corneal melting are in-
fection, vitamin A deficiency, collagen vascular disease,
severe Sjögren’s syndrome and neurotrophic keratitis
[10]. Each of these causes could be excluded in this pa-
tient, based on his medical history, his clinical symptoms
and signs, and the results of the laboratory studies.
Thus, an immunologic mechanism that arose directly
from PNP might be associated with this patient’s corneal
melting. However, the exact reason for the corneal melt-
ing and the relationship between CD-associated PNP
and corneal melting remain to be elucidated.
CD is a rare neoplasm of lymphatic origin. The
pathogenesis of CD-associated PNP remains unknown,
although several hypotheses have been postulated, such as
the secretion of autoantibodies from the tumor and the
cross-reactivity of tumor antigens with epidermal antigens
[2, 11]. Although a complete resection of a localized
Castleman’s tumor could treat the disease and improve
mucocutaneous lesions in most of patients [2, 7, 8], serum
autoantibodies in some reports [12] and in this patient in-
deed remained detectable for as long as 2–4 years after
surgery without recurrence of the tumor, suggesting that
the immune reaction persisted. This might be the cause of
the recurrence of mucosal lesions and the occurrence of
corneal melting in this patient. It is necessary, therefore,
to maintain effective immunosuppression for a prolonged
postoperative period.
Currently, there is no standard therapy for conjunctival
and corneal lesions from CD-associated PNP because of
the rarity of this complication. As chronic cicatrizing
conjunctivitis is more likely to occur in PNP, Tam et al.
[13] proposed management with adequate lubrication,
prophylactic antibiotics and corneal protection to reverse
Fig. 3 The ocular presentation. a The right conjunctiva gradually developed symblepharon, pterygium and hypophasis. b Six months after ocular
surgery, recurrent pterygium and a 2 mm-diameter aseptic corneal ulcer developed in the nasal paracentral non-surgical area in the right eye.
c To date, corneal melting has been stable; in the right eye, the epithelium is intact, and mild conjunctival congestion and temporal pterygium
are present
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the underlying cause, to prevent symblepharon formation
and to maintain the ocular surface. The successful local
tacrolimus and cyclosporine treatment of corneal melting
in the patient suggested that local immunosuppression in
addition to systemic immunomodulatory therapy is critical
for the treatment of corneal melting.
Conclusion
This case highlights the potential for CD-associated PNP
to present with corneal ulceration, which may lead to
blindness along period after the complete excision of
localized neoplasms. Systemic and local immunosup-
pression administrations are essential for the treatment
of corneal complications. Further studies are needed to
elucidate the exact mechanism of corneal melting in
CD-associated PNP.
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